Valuation: KalVista Pharma

Market Cap 1.44B 1.26B 1.19B 1.09B 2.03B 138B 2.05B 14.3B 5.54B 70.23B 5.4B 5.28B 229B P/E 2024
-2.46x
P/E 2025 -5.3x
Enterprise Value 1.42B 1.25B 1.18B 1.08B 2.01B 136B 2.03B 14.14B 5.48B 69.45B 5.34B 5.22B 226B EV / Sales 2024
-
EV / Sales 2025 10.9x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+0.04%
6 months+64.03%
Current year+67.18%
Current year 14.22
Extreme 14.22
27
1 year 10.41
Extreme 10.41
27
3 years 7.21
Extreme 7.21
27
5 years 4.12
Extreme 4.12
27
10 years 0
Extreme 0
45
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2016-10-31
Chief Executive Officer 61 2024-03-05
President - 2026-06-10
Director TitleAgeSince
Chairman - 2026-06-10
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Exercice

Executive/Senior Manager

101,400 0.2006%
5/26/26 Sell

Executive/Senior Manager

-1,489 0.0029%
5/26/26 Sell

Executive/Senior Manager

-1,966 0.0039%

Financials

2024 2025
Net sales - 73.62M 64.75M 61.04M 55.69M 104M 7.07B 105M 733M 284M 3.6B 276M 270M 11.7B
Net income -127M -111M -105M -95.81M -179M -12.16B -181M -1.26B -488M -6.19B -475M -465M -20.13B -164M -145M -136M -124M -232M -15.77B -234M -1.63B -633M -8.03B -617M -603M -26.12B
Net Debt -203M -179M -168M -154M -287M -19.49B -290M -2.02B -783M -9.92B -762M -746M -32.29B -16.01M -14.08M -13.27M -12.11M -22.65M -1.54B -22.82M -159M -61.72M -782M -60.1M -58.8M -2.54B
Logo KalVista Pharma
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. KALV Stock